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Abstract  
The homing molecule, L-selectin (CD62L), is commonly used as a T cell activation marker, 
since expression is downregulated following engagement of the T cell receptor. Studies in mice 
have shown that CD62L+ central memory T cells are better at controlling tumour growth than 
CD62L- effector memory T cells, while L-selectin knockout T cells are poor at controlling 
tumour growth.  Here, we test the hypothesis that T cells expressing genetically modified forms 
of L-selectin that are maintained following T cell activation (L-selectin enhanced T cells) are 
better at controlling tumour growth than wild type T cells. Using mouse models of adoptive 
cell therapy, we show that L-selectin enhancement improves the efficacy of CD8+ T cells in 
controlling solid and disseminated tumour growth. L-selectin knockout T cells had no effect.  
Checkpoint blockade inhibitors synergised with wild type and L-selectin enhanced T cells but 
had no effect in the absence of T cell transfers. Reduced tumour growth by L-selectin enhanced 
T cells correlated with increased frequency of CD8+ tumour infiltrating T cells 21 days after 
commencing therapy.  Longitudinal tracking of Zirconium-89 (89Zr) labelled T cells using 
PET-CT showed that transferred T cells localise to tumours within 1 hour and accumulate over 
the following 7 days.  L-selectin did not promote T cell homing to tumours within 18 hours of 
transfer, however the early activation marker CD69 was upregulated on L-selectin positive but 
not L-selectin knockout T cells.  L-selectin positive and L-selectin knockout T cells homed 
equally well to tumour-draining lymph nodes and spleens.  CD69 expression was upregulated 
on both L-selectin positive and L-selectin knockout T cells but was significantly higher on L-
selectin expressing T cells, particularly in the spleen. Clonal expansion of isolated L-selectin 
enhanced T cells was slower, and L-selectin was linked to expression of proliferation marker 
Ki67. Together these findings demonstrate that maintaining L-selectin expression on tumour-
specific T cells offers an advantage in mouse models of cancer immunotherapy. The beneficial 
role of L-selectin is unrelated to its’ well-known role in T cell homing and, instead, linked to 
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activation of therapeutic T cells inside tumours. These findings suggest that L-selectin may 
benefit clinical applications in T cell selection for cancer therapy and for modifying CAR-T 
cells to broaden their clinical scope. 
Introduction   
Immunotherapy represents a paradigm shift in cancer treatment; instead of directly attempting 
to kill cancerous tissue through radio- or chemotherapy, the patient’s immune system is 
targeted, with the aim of augmenting the anti-tumour immune response. This may be done via 
systemic delivery of monoclonal antibodies that inhibit immune checkpoints exploited by 
tumours to induce immune tolerance, such as α-PD-1 (pembrolizumab, nivolumab) (1) or α-
CTLA-4 (ipilimumab) (2). These pioneering immunotherapies are effective alone but behave 
synergistically to produce the most pronounced clinical effects when used together (3). The 
clinical outcomes of this approach have been dramatic, but the range of cancers amenable to 
checkpoint inhibition is limited and is thought to rely heavily on the cancer having a high 
neoantigen load (4). Many cancers, however, have only low to medium somatic mutation rates, 
leading to a limited range of neoantigens (4). Furthermore, T cells that are specific for cancer 
antigens often have only low affinity T cell receptors (TCRs) (5), limiting the efficacy of the 
endogenous T cell response, even in the presence of checkpoint inhibition.  
To circumvent this, another class of immunotherapy involves adoptive transfer of T cells 
(adoptive cell therapy, ACT) into the patient. Initially, this approach was based on recovering 
tumour-infiltrating T cells (TILs) from resected cancers, expansion ex-vivo, and then re-
infusion back to the patient. However, as understanding of the interaction between immune 
cells and tumour cells has increased, this approach has expanded to include a number of 
different strategies. Chimeric antigen receptor T (CAR-T) cells circumvent the need for a high-
affinity tumour antigen-specific TCR by replacing the extracellular portion of the TCR with a 
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monoclonal antibody receptor. This entirely bypasses the standard antigen presentation 
pathway, allowing CAR-T cells to be selectively targeted to the tumour tissue. However, to 
date, most CAR-T cells have been used to treat circulating haematological malignancies (6). 
Applying this technology to solid tumours has proved challenging, with one key obstacle being 
trafficking of T cells into tumours that are poorly vascularized (7, 8).  The complexity of the 
tumour microenvironment means that some therapeutic approaches that directly target the 
tumour can also indirectly improve immune responses. Anti-angiogenic therapies were 
designed to induce tumour death via hypoxia. However, inhibiting rapid and abnormal 
angiogenesis had the unexpected effect of normalizing the tumour vasculature (9), and thus 
allowing improved infiltration of both chemotherapeutic agents and immune cells into the 
tumour. Indeed, the complexity of cross-talk between the immune system and cancer 
vasculature is only now being fully appreciated (10).   
The leucocyte adhesion molecule L-selectin (CD62L) is a type-I transmembrane lectin receptor 
expressed on the surface of leucocytes. It is part of the selectin family, which also includes E-
selectin (CD62E), expressed on endothelial cells, and P-selectin (CD62P), which is expressed 
on platelets and activated endothelium. L-selectin regulates entry of naïve and central memory 
T cells into lymph nodes and activated CD8+ T cells to sites of virus infection (11); L-selectin 
expression is regulated via proteolytic shedding of the ectodomain and transcriptional silencing 
of the L-selectin gene (12, 13). Downregulation of L-selectin on T cells is known to take place 
following engagement of the TCR, and this has led to L-selectin being used as a marker of T 
cell activation. It has been demonstrated that T cells with a naïve/central memory CD62L+ 
phenotype are better at controlling solid tumour growth than CD62L- cytotoxic T cells (CTLs) 
in mice (14, 15). However, even when matched for differentiation status, T cells from L-
selectin knockout mice are less effective than wild type T cells suggesting a direct role for L-
selectin in controlling tumour growth (14). We hypothesise that cells which are genetically 
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engineered to express high levels of mutant L-selectin which cannot be shed or gene-silenced 
would offer improved control of solid tumour growth, through increased T cell recruitment and 
infiltration of the tumour stroma. In this mutant L-selectin, the membrane-proximal region of 
CD62L has been replaced with the proteolysis-resistant membrane-proximal region of CD62P.  
We have therefore designated this modification as LΔP-selectin. In addition, the modified LΔP-
selectin is expressed under a human CD2 promoter and locus control region which abrogates 
transcriptional silencing (16, 17). This study addresses whether these novel constructs serve to 
improve T cell-based cancer immunotherapy for solid and disseminated tumours.  
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Materials and Methods 
Mice 
Genotypes of mouse strains used in the study are shown in Table 1. C57BL/6J (B6) mice were 
purchased from Charles River, congenic B6.PL-Thy1a/CyJ mice, designated Thy1.1 hereafter, 
and FoxP3DTR mice, supplied by Alexander Rudensky and maintained as previously described 
(18), were bred in house. L-selectin transgenic mice expressing wild type murine L-selectin 
(CD62Lwt) or a non-cleavable mutant L-selectin (CD62LP) on a B6 L-selectin-/- background 
have been described (16, 19). F5 TCR transgenic mice generated as described previously (20), 
were backcrossed to B6 mice and maintained as a homozygous colony (F5B6).  F5B6 mice 
were backcrossed to B6 L-selectin-/- mice and maintained as a homozygous colony (F5L-
selKO). CD62LΔP mice were backcrossed to F5L-selKO and maintained as a homozygous 
colony (F5LΔP). Hemizygous F5 mice were generated by crossing F5B6 with B6 mice and the 
F1 generation (F5/B6) used. T-cell donors and tumour-bearing hosts were gender matched.  
Mice were housed in a specific pathogen free facility and allowed free access to water and 
food.  Experimental mice were housed in individually ventilated cages.  All mouse experiments 
conformed to the British Home Office Regulations (Animal (Scientific Procedures) Act, 1986; 
Project License PPL30/3188 to Prof Ann Ager) and the protocol was approved by the Animal 
Welfare and Ethical Review Body at Cardiff University.  
Adoptive T cell therapy 
CD8+ T cells were isolated from pooled splenocytes and lymph nodes of naïve mice using a 
CD8a+ T cell isolation kit for negative selection, and LS columns, according to the 
manufacturer’s instructions (StemCell Technologies) from 10.00-12.00 GMT on the day of 
injection. Briefly, spleens and/or lymph nodes were harvested from adult mice and mashed 
through a 70 µm cell strainer (BD Pharmingen). Red blood cells were lysed using red cell lysis 
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buffer (Biolegend) and lymphocytes washed with ice-cold phosphate buffered saline (PBS) 
supplemented with 2 % foetal calf serum (FCS) prior to magnetic isolation. The enriched 
CD8a+ cell fraction was counted using a hemocytometer, resuspended in sterile PBS for 
injection and analysed for CD8, CD62L, CD44, CD27 and F5 TCR expression.   
CTLs were generated as described previously (11). Briefly,  CD8+ T cells from naïve mice (2 
x 106 cells/well) in 24-well plates (Nunclon) in complete medium (DMEM supplemented with 
10% FCS, penicillin-streptomycin, L-glutamine, non-essential amino-acids and 2-
mercaptoethanol were incubated with 6 x106 NP68-peptide (ASNENMDAM; Peptide 
Synthetics) pulsed irradiated splenocytes (5 µm NP68 peptide for 1 hour at 37oC, irradiated at 
3000 cGy), and plates incubated at 37°C in 5% CO2. Fresh complete medium supplemented 
with 360 IU/ml hrIL-2 was added after 2 days and replaced with fresh medium on day 5.  CTLs 
were harvested at day 7.  
Tumour cell lines 
The NP68-B16 melanoma cell line was generated as described previously (21, 22) and used to 
study adoptive T cell immunity to tumours in mice.  Cells were validated for NP68 expression 
and confirmed mycoplasma free.  In some experiments, the parental B16F10 melanoma cell 
line (ATCC number CRL-6475) was used to study endogenous T cell dependent immunity to 
tumours, as described previously (23). 
Solid tumour model 
Frozen B16-F10 or NP68-B16 cells were thawed from liquid nitrogen and cultured until first 
passage reached 100% confluence. Upon confluence, the cells were dislodged using StemPro 
Accutase (ThermoFisher Scientific) at 37oC and resuspended at 5 x 105 cells in 200μl sterile 
PBS.   NP68-B16 cells were injected subcutaneously into the shaven left flank of B6, Thy1.1 
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or Foxp3DTR mice. B16F10 cells were injected subcutaneously into the shaven left flank of 
B6, CD62Lwt or CD62LΔP mice. Mice were randomized into treatment groups for each 
experiment of 8-10 mice per group, tumour cells injected at 13.00-15.00 GMT and mice 
returned to their home cage. Tumours were measured every 3-4 days using digital calipers and 
tumour size calculated as the product of two perpendicular diameters.  
For adoptive T cell therapy, NP68-B16 tumour bearing mice were sub-lethally irradiated with 
597cGy total body irradiation (TBI) on day 6 following tumour cell injections. On day 7, mice 
were injected subcutaneously with 100µg NP68 peptide in incomplete Freund’s adjuvant (IFA; 
final volume of 200µl) into the right flank prior to injection of T cells into the tail vein. T cells 
and peptide were injected at 14.00-16.00 GMT and mice returned to their home cage. The 
checkpoint inhibitor, InVivoPlus anti-mouse PD-1, clone RMP1-14 (2BSCIENTIFIC) was 
injected on Day 10, 13 and 16 and InVivoMab anti-mouse CTLA-4 (CD152), clone 9H10, on 
Day 9, 12 and 15 (100 µg per injection). Other groups were treated with InVivoMAb rat IgG2a 
Isotype control (BE0089; 2BSCIENTIFIC) on the same days, times and doses as anti-PD-1 
and InVivo MAb polyclonal Syrian Hamster IgG (BE087, 2BSCIENTIFIC) on the same days, 
times and doses as anti-CTLA-4. Antibodies were administered at 10.00-12.00 or 14.00-16.00 
GMT and mice returned to their home cage.  
To study the effect of regulatory T cell depletion, non-irradiated, NP68-B16 tumour-bearing 
FoxP3DTR mice were injected intraperitoneally with 2.5µg/kg or 5µg/kg diphtheria toxin (DT) 
3 times a week or 100mg/kg or 200mg/kg cyclophosphamide (CY) in 10% DMSO in PBS once 
a week starting a day 7 following tumour inoculation. A control group of tumour-bearing 
FoxP3DTR mice received an equal volume of 10% DMSO in PBS once a week. Treatments 
were administered at 10.00-12.00 or 14.00-16.00 GMT and mice returned to their home cage.  
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At the end of the experiment, blood was collected from each mouse by cardiac puncture, serum 
prepared and stored frozen at -80oC. Tumours were excised, and either fixed in 10% neutral 
buffered formalin (NBF) and embedded in paraffin wax, or snap-frozen in OCT without 
fixative, or, in some cases, large tumours were bisected and treated with both preservation 
methods.  Tumour growth rates were calculated as described previously (18). Briefly, tumour 
growth rate (k, days−1) was determined using a statistical software package Prism 5 
(GraphPad) with the following equation for exponential growth: Y = Y0 × exp(k × X). Tumour 
diameter (X, mm) was measured every 3-4 days using calipers. On average, measurements 
were taken for 23 days for both untreated mice and F5 T cell treated mice. On average 5-7 
measurements were used to calculate tumour growth rate. 
Disseminated tumour model 
B6 mice were exposed to 597 cGy TBI on day 1 and randomly assigned to treatment groups of 
8 mice for each experiment. For the therapeutic model, 5 x 106 NP68-B16 tumour cells were 
injected intravenously on day 2. On day 4, 3.4 x 104 T cells were injected intravenously, 
followed by subcutaneous administration of NP68 peptide in IFA (Fig. 3A). For the 
prophylactic model, timings of the tumour and T cell injections were reversed (Fig. 3A). Mice 
were monitored until day 13 or 14 and then sacrificed. The lungs were excised, weighed, fixed 
in 10% NBF and embedded in paraffin wax.  5 µm sections were stained with haematoxylin 
and eosin an d tumour nodules analysed by microscopy. In some studies, Thy 1.1 mice were 
injected with NP68-B16 tumour cells and the number and activation status of donor F5 T cells 
(Thy1.2+ CD8+) in the lungs at end stage (day 14) were determined by flow cytometry 
following tissue disaggregation.   
L-selectin dependent T cell homing  
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A short-term homing assay in which the recruitment of L-selectin expressing, and L-selectin 
deficient T cells are compared directly in individual mice was used as described previously 
(11). Briefly, Thy1.1 mice were subcutaneously injected with 1.5 x 106 NP68-B16 tumour cells 
and tumours grown for 7-14 days. Thy1.1 mice served as non-tumour bearing mice. Tumour 
bearing mice and non-tumour bearing mice received 597cGy TBI. CD8+ T cells isolated from 
naïve F5LP and F5LselKO (both Thy1.2) were mixed 1:1 (numbers determined by 
haemocytometer, and confirmed by flow cytometry using Cytocount beads) and a total of 6 – 
10 x106 T cells injected intravenously into mice at 14.00-16.00 GMT on the day following 
irradiation. All mice received 100µg NP68-IFA s.c. prior to T cells. The next morning (10.00-
11.00 GMT; 18 h following T cell injections), mice were culled and tissues including blood, 
spleen, tumour-draining and peptide-draining lymph nodes, non-draining lymph nodes and 
tumour were collected. Tumours were disaggregated using gentle MACS (Miltenyi). 
Lymphoprep was used to isolate immune cells from blood and tumour by centrifugation. 
Following isolation, cells were stained for CD8, Thy1.2 and L-selectin, analysed by flow 
cytometry and L-selectin expression on donor CD8+, Thy1.2 cells determined.  Cell numbers 
were determined using Cytocount beads (Dako).  
Longitudinal tracking of adoptively transferred T cells using micro PET/CT imaging 
89Zr was produced via proton bombardment of an Yttrium target via an adaptation of the 
methods of Walther et al (24) and Dabkowski et al (25). Briefly, a disk of natural abundance 
89Y foil (300 µM thick, goodfellow) in a custom made aluminium holder was loaded into a 
COSTIS Solid Target System (STS) fitted to an IBA Cyclone (18/9) cyclotron equipped with 
a 400 µM thick niobium beam degrader. The disk was irradiated for 4 h with a beam energy of 
40 µA. The irradiated disk is left in the cyclotron for 12 h to allow any short lived 89MZr to 
decay to 89Zr before removal for purification (activity 1.5-2GBq). The disk was dissolved in 
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2M HCl with stirring and heat and the 89Zr was isolated by flowing over a hydroxymate 
functionalised ion exchange resin column (prepared in house freshly for each separation). The 
column was rinsed with 2M HCl and water to remove 89Y before the 89Zr was liberated with 
1M oxalic acid in 3 × 1 ml fractions. The most concentrated fraction contained 800-1000MBq. 
89Zr Oxine for cell labelling was prepared via an adaptation of the methods of Ferris e al (26). 
Freshly prepared 89Zr Oxalate (200 µl, ~150-200 MBq) was adjusted to pH 7.0 with 0.5 M 
Na2CO3 (~270-390 µl) and diluted to 2 ml with distilled water in a 15 ml centrifuge tube. To 
this was added 2 ml of oxine solution in chloroform (1mg/ml) and the resultant biphasic 
mixture was shaken at room temperature (RT) at 1000 rpm for 1 hour. The mixture was then 
allowed to settle and the lower chloroform layer was removed and the activity measured by 
dose calibrator (typically 1-20MBq). A further 2ml of oxine chloroform solution was added to 
the remaining aqueous phase and the mixture was shaken overnight (1000 rpm, RT). The 
resultant mixture was allowed to settle and the chloroform layer removed and the activity 
measured (typically 100-150 MBq). The chloroform was removed by heating and gentle stream 
of air until a dry dusty yellow crust remained in the vial. This was redissolved in DMSO (20 
µl) and then made up to 2 ml with PBS for cell labelling. 
CD8+ T cells were isolated from spleens and lymph nodes of naïve F5B6 and F5LΔP mice, 
resuspended to 13-66 x 106/ml in PBS and incubated with 89Zr oxine (26-65 MBq) with shaking 
at 550 rpm for 30 min at RT. Unincorporated 89Zr oxine was removed by repeated washing in 
10 ml PBS,  cells collected by centrifugation (350g, 5 min, RT) and supernatant checked for 
removal of free 89Zr. Uptake of 89Zr oxine by CD8+ T cells was 18-20% efficient, with labelled 
cell yields of between 30 and 50% and viability >90%. 8-17 x 106 T cells labelled with 0.7-
1.63 MBq 89Zr were resuspended in 200 µl PBS for injection into sub-lethally irradiated, 
tumour-bearing mice.  100 µg NP68-IFA was injected s.c. prior to the T-cell injection. Mice 
were anaesthetised with isofluorothane (5% in O2 gas 1-2 l/min) and 
89Zr labelled T cells 
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injected intravenously.  Mice were then injected with iopamidol contrast agent (Niopam 300, 
Bracco100µl/mouse ip) and mice were scanned in a Mediso PET/CT Preclinical Imaging 
System (nanoScan122S PET CTMediso). Respiration was monitored with a pressure pad 
connected to differential pressure transducers for low-range pressure monitoring during the 
entire PET-CT examination and anesthesia was maintained through the nose cone of the bed 
(1~2% isoflurane in O2 gas 1-2 l/min).  PET emission data were collected for 60 min. Spatial 
resolution of PET measurements was 0.4 mm and energy lower/upper limit was 400/600. The 
CT scan parameters were set as follow: tube voltage was 50 kVp, tube current was 1 mA, 
exposure time 300 ms and maximum number of projections was 400. Reconstructed resolution 
of CT was 0.25 mm. PET-CT scans were repeated at 20, 44, 68, 140, 188, 212, and 235 h 
following T cell injections. Whole body radioactivity was independently measured 
immediately after scanning by placing the anaesthetised mouse in a Capintec CRC-25 dose 
calibrator on calibrator setting 465. 
PET/CT scans were analysed using Vivo Quant software (inviCRO). Regions of interest were 
drawn over tumour, lung and skeleton for each mouse. Total radioactivity in each organ was 
calculated and expressed as percentage of total measured radioactivity in the mouse at each 
timepoint.  
Flow cytometry 
Cells were stained with fixable LIVE/DEADTM Aqua dye as per the manufacturer’s protocol 
(Invitrogen), treated with 50nM dasatinib (Sigma) to prevent TCR downregulation, then 
stained with PE-conjugated NP68 tetramer at 37°C, followed by surface antibodies at 4°C as 
follows: anti-TCRVβ11-FITC, anti-CD8-PerCPCy5.5, anti-CD27-BV421, anti-CD44-
APCCy7, anti-CD62L-PECy7 and anti-CD69-APC (all BioLegend). Cells were fixed with 
10% formalin and data collected using a BD FACSCanto II within 4 days of staining. Between 
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fixing and data collection, cells were stored in PBS 2% FCS at 4oC in the dark. Voltages and 
compensation were set using OneComp eBeads (eBioscience) and Arc-reactive beads 
(Invitrogen) and the FACSDiva automatic compensation function. CytoCount beads were used 
to quantify cell numbers, according to the manufacturer’s instructions (Dako). Figures were 
prepared using FlowJo software (TreeStar Inc.). 
Immunohistochemistry 
Formalin-fixed paraffin-embedded tumour tissue was cut into 5μm sections and rehydrated. 
Antigen retrieval was performed using Tris-EDTA buffer (10mM Tris, 1mM EDTA, pH9). 
Sections were blocked with 0.5% H2O2 in methanol, rinsed in PBS, blocked with horse serum 
(Vector Laboratories) and stained overnight with rabbit polyclonal anti-CD3 (A0452, Dako) or 
rabbit polclonal anti-CD8 ((BS-0648R, Biosciences). After staining with horse anti-rabbit-
HRP (Vector Laboratories), sections were developed for 90-120 sec with SG detection solution 
(Vector Laboratories). Slides were mounted using DPX (Fisher Chemical). Sections were 
photographed at 20X magnification using an EVOS XL Core Microscope (Thermo Fisher 
Scientific).  
Quantification of CD3 and CD8 staining 
The whole tumour area was photographed at 20X magnification. Five sequentially numbered 
fields of view (FOV) were analysed per tumour. Where 5-6 FOV were taken, images 1-5 were 
analysed; for 7-8 FOV, images 1, 3-5, 7 were analysed; for 9 FOV, images 1, 3, 5, 7 and 9 were 
analysed. Images were analysed using the Fiji version of ImageJ. The scale was set to 3.4 pixels 
= 1μm (based on image scale bar). Non-specific staining was subtracted using Background 
Correction, and the images were separated into FastRed, FastBlue and DAB using Color 
Deconvolution. The FastBlue image was used to analyse CD3 and CD8. Minimum image 
threshold was set at 87, and maximum image threshold was set at 173-210. Percent area was 
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analysed and plotted. In cases where the tumour section did not cover the whole FOV, the blank 
area was subtracted prior to analysis. Four to twelve tumours were analysed per treatment 
group.  
Soluble L-selectin  
Serum levels of L-selectin in tumour-bearing mice were quantified using a mouse L-
Selectin/CD62L DuoSet ELISA (R & D Systems) and optical densities measured on a CLARIO 
microplate reader (430-0841). 
Statistics and figures 
Statistical analyses were performed in Prism 7 (GraphPad Software Inc.) as detailed in figure 
legends. Figures were prepared using FlowJo software (Treestar Inc), Prism 7 (GraphPad 
Software Inc.), MS Powerpoint and Adobe Illustrator.  
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Results 
Solid tumour model to study T cell-dependent tumour immunotherapy 
To measure T cell responses in tumour-bearing mice we used a modified B16F10 cell line 
expressing the H2Db-restricted internal influenza nucleoprotein epitope NP68 (NP68-B16) as 
a surrogate tumour antigen (22). The lowest tumour cell dose that would consistently result in 
tumour growth in host animals was 5x105 cells per animal and this dose was used throughout 
this paper.  We used CD8+ T cells transgenic for the F5 TCR, which is specific for NP68 (20), 
as a source of tumour-specific T cells. Initial studies involved adoptive transfer of in-vitro 
activated CTLs expressing different levels of F5 TCR.  CTLs hemizygous for F5 (F5B6/B6; 
Table 1) were not able to control the growth of NP68-B16 tumours (Fig. 1A).  However, F5B6 
CTLs expressing increased levels of F5 TCR were able to control tumour growth (Fig. 1A). 
We have previously shown that CTLs hemizygous for F5 control pulmonary influenza virus 
infections (11); the increased level of TCR required to control tumour growth most likely 
reflects the necessity to overcome tumour-induced immunosuppression. When we compared 
the ability of CD8+ T cells from naïve mice to CTLs, T cells from naïve mice were considerably 
more efficacious, with a dose of only 5x105 T cells having the equivalent effect to 2x107 in 
vitro-stimulated CTLs (Fig 1A). All subsequent experiments were conducted with CD8+ T cells 
freshly isolated from naïve mice, unless detailed otherwise.  
To dissect the role of the host’s immune system in this model, we transplanted the NP68-B16 
tumour cells into FoxP3DTR mice. These mice express the diphtheria toxin receptor on cells 
positive for the transcription factor FoxP3, which is expressed by regulatory T cells (Tregs). 
Once the tumours had been allowed to grow for 7 days, tumour-bearing mice were treated with 
5μg/kg diphtheria toxin (DT), to deplete Tregs (Fig. 1B). This treatment completely halted 
tumour growth, indicating a very strong role for Tregs in restricting the growth of NP68-B16 
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melanomas. This also demonstrated that, once relieved of suppression by Tregs, the growth of 
solid tumours could be controlled by host T cells. The chemotherapeutic agent 
cyclophosphamide (CY) is thought to preferentially kill Tregs at low doses, due to their rapid 
division (27). Comparison of the prevalence of circulating Tregs in tumour-bearing hosts 
following either DT or CY treatment showed that 100mg/kg CY affords a similar level of Treg 
depletion as DT treatment in FoxP3DTR mice (Fig. 1C). Furthermore, treatment with 100mg/kg 
CY gave the same level of tumour growth control as DT treatment (Fig. 1D). In contrast, 
treating tumour-bearing hosts receiving a non-lethal dose of radiation, together with a bolus of 
NP68 peptide in incomplete Freund’s adjuvant (peptide-IFA) led to an increase in tumour 
growth (Fig. 1D). Increased growth of NP68-B16 tumours following sub-lethal irradiation 
could reflect a loss of endogenous T cells which partially control tumour growth or a response 
to locally-induced inflammation which is known to promote tumour growth (28). Non-lethal 
doses of irradiation are commonly used to create niche space prior to adoptive cell transfer 
(ACT), and this pre-conditioning regime is employed throughout this paper. It is important to 
note that despite the clinical use of radiation for cancer treatment, in this model system, 
irradiation alone does not control tumour growth, and, in fact, accelerates growth. The final 
aspect of the model to establish is the therapeutic dose of T cells required to control tumour 
growth. In Figure 1E, we demonstrate that differing levels of tumour growth control can be 
produced by just five-fold differences in F5 CD8+ T cell dose whereas equivalent doses of 
polyclonal CD8+ T cells do not control tumour growth (Fig. 1E). 
We have demonstrated that the growth of NP68-B16 melanoma relies is controlled by the host 
immune system, including the use of Tregs to escape immune cell attack. However, in fully 
immunocompetent (non-irradiated) tumour bearing mice, the host immune response to NP68-
B16 melanoma is not sufficient to control tumour growth (Fig. 1D).  Given this, we would 
expect checkpoint inhibitors to improve the control of these tumours, through augmentation of 
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the host immune response. However, when tumour bearing mice are treated with anti-CTLA-
4 monoclonal antibodies, mimicking the clinical ipilimumab therapy, improved control of 
tumour growth is only seen in conjunction with adoptive transfer of F5 T cells (Fig. 1F). This 
demonstrates that although there is evidence in Figure 1D for a modest host immune response 
to the tumours, it remains insufficient for tumour control, even in the presence of checkpoint 
inhibition. This is in line with previously published observations of the poor immunogenicity 
of the unmodified B16 melanoma cell line (29). However, treatment with even a very low dose 
of anti-CTLA-4 acts synergistically with low dose ACT to produce striking control of tumour 
growth, even where ACT alone was not effective. The same powerful synergy is seen with 
anti-PD-1 monoclonal antibody treatment (Fig. 1G).  
L-selectin enhanced T cells in adoptive cell therapy for solid tumours 
Subcutaneous B16-F10 melanomas show accelerated growth in L-selectin knockout mice (30) 
but which L-selectin expressing leucocyte population controls B16-F10 melanoma growth was 
not determined.  To study the role of L-selectin on T cells we generated gain-of-function L-
selectin transgenic mice in which T cells express either wildtype (CD62Lwt) or a shedding-
resistant form of L-selectin (CD62LΔP) expressed under a heterologous promoter which we 
have shown to abrogate cytokine induced transcriptional silencing in virus-infected mice (11, 
13, 17).  When parental B16-F10 cells are transplanted into CD62Lwt mice, tumour growth 
was not significantly different than in the background C57BL/6 (B6) strain (Fig. 2A), 
indicating that abrogating gene silencing on its own in CD62Lwt mice does not boost anti-
tumour immunity over and above that seen in wildtype B6 mice expressing endogenous L-
selectin.  When parental B16-F10 cells are transplanted into CD62LΔP mice, tumour growth 
is significantly slower than in B6 and CD62Lwt mice strain with survival of 80% CD62LΔP 
mice compared with <40% in B6 and CD62Lwt mice (Fig. 2A). These data demonstrate that 
abrogating ectodomain shedding as well as transcriptional silencing of L-selectin boosts T cell-
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dependent tumour immunity. Interestingly, this finding suggests that the abrogation of 
shedding, rather than gene silencing, plays a dominant in promoting T cell dependent immune 
responses even against poorly immunogenic unmodified B16 melanoma cell line (29). 
CD62LΔP mice do not express endogenous L-selectin and expression of transgenic L-selectin 
is restricted to T cells (16).  Together these data indicate that L-selectin expressed by T cells, 
and not by other leucocytes, regulates the growth of B16-F10 melanomas. These data strongly 
support our hypothesis that L-selectin enhancement by maintaining expression on activated T 
cells improves T cell dependent immunity to tumours.   
To determine whether this effect was due to the action of enhanced expression of L-selectin on 
antigen-specific T cells, CD8+ T cells from transgenic mice homozygous for both the F5 TCR 
and CD62LΔP (F5LΔP) were transferred into C57BL/6 mice with established NP68-B16 
melanomas (Fig. 2B). Expression levels of L-selectin and the transgenic F5 TCR were 
confirmed by flow cytometric analysis of transferred T cells (Figure 2C). Whilst CD8+ T cells 
expressing endogenous, wildtype L-selectin (F5B6) were unable to control tumour growth, L-
selectin enhanced F5LΔP T cells produced a significant reduction in tumour growth rate (Fig. 
2B). To expand upon this, we repeated this study with F5 T cells that were either knockout or 
wildtype for L-selectin, and compared them to F5LΔP T cells (Fig. 2D). As before, tumours 
were established for 7 days before ACT, and, as would be expected from the findings of 
Gattinoni et al (14), cells that are knockout for L-selectin (F5LselKO) are unable to control 
tumour growth (Fig. 2D). In contrast, F5LΔP T cells offer significantly improved control over 
F5B6 cells (Fig. 2D). The improved control of tumour growth may be seen in more detail by 
viewing the individual tumour growth curves for each mouse, displayed as average curves in 
Figure 2E. 
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Ectodomain shedding of L-selectin on T cells and other leucocytes releases soluble L-selectin 
into the bloodstream which can compete for ligands on blood vessels and restrict L-selectin 
dependent leucocyte recruitment (31). Blood levels of soluble L-selectin in F5LΔP and LΔP 
mice are <5 % of those in matched control mice expressing wildtype L-selectin due to lack of 
homeostatic and activation induced shedding (16, 19).  To determine if the increased efficacy 
of F5LΔP T cells is dependent on altered blood levels of soluble L-selectin, soluble L-selectin 
in peripheral blood was measured at the time of tumour harvest.  As shown in Figure 2F, soluble 
L-selectin was detected in tumour-bearing mice in the complete absence of T cell transfers. 
Moreover, levels of soluble L-selectin did not change following transfer of F5L-selKO T cells, 
F5B6 T cells or F5LΔP T cells (Fig. 2F) showing clearly that soluble L-selectin in tumour-
bearing mice is not derived from injected donor T cells but, instead, is derived from host 
leucocytes. Interestingly, soluble L-selectin levels in tumour-bearing mice were 60% lower 
than in age- and sex-matched, naive C57BL/6 mice. Although not investigated further, this 
may be due to reconstitution of the immune system following sublethal irradiation. Together, 
these findings show that the increased efficacy of F5LΔP over F5B6 and F5LselKO T cells 
was not dependent on altered blood levels of soluble L-selectin in tumour-bearing mice, but 
instead depended on increased and maintained expression of L-selectin at the surface of F5LΔP 
T cells.  
To assess the potential for L-selectin enhanced T cells to complement other immunotherapeutic 
strategies, we determined the efficacy of F5LΔP T cells in the presence and absence of PD-1 
blockade.  In figures 2B and 2D, the benefit of maintained expression of L-selectin over wild 
type in the treatment of solid tumours is clearly shown. When F5LΔP T cells are combined 
with anti-PD-1 therapy, a striking synergistic effect is seen, with tumour growth being arrested 
following combinatorial treatment (Fig, 2G), demonstrating the clear potential of combining 
F5LΔP T cells with checkpoint blockade inhibition.  
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L-selectin enhanced T cells in adoptive cell therapy for disseminated tumours  
To determine if L-selectin enhanced T cells confer protection against disseminated tumours, 
we used NP68-B16 tumour cells administered via the bloodstream which results in colonization 
of the lungs in the absence of a primary solid tumour.  We tested the impact of enhanced L-
selectin on the outcome of T cell therapies delivered either before or after intravenous injection 
of tumour cells.  In a prophylactic model, F5 T cells (Thy1.2) expressing variable levels of L-
selectin were injected intravenously into sub-lethally irradiated (Thy1.1) mice and mice 
vaccinated in the right flank with NP68 peptide in adjuvant. NP68-B16 tumour cells were 
injected intravenously the following day.  In a therapeutic model, NP68-B16 tumour cells were 
intravenously injected into sub-lethally irradiated mice and allowed to colonise the lungs. Two 
days later, F5 T cells expressing variable levels of L-selectin were injected intravenously and 
mice vaccinated in the right flank with NP68 peptide in adjuvant (Fig 3A). In both models, 
mice were harvested 2 weeks after tumour administration, lungs excised, and tumour loads 
determined by total lung weight and confirmed by histology.  F5 T cells deficient in L-selectin 
or expressing wildtype L-selectin did not affect tumour loads in either the prophylactic or 
therapeutic models when compared with tumour-bearing mice that did not receive T cells (Fig. 
3B).   However, F5LΔP T cells significantly reduced tumour load in both models and average 
lung weights reduced from 463 mg in untreated mice to 277 mg following F5LΔP T cell therapy 
which approached that of age- and sex-matched non-tumour bearing mice at 180 mg (Fig. 3B). 
The improved efficacy of F5LΔP T cells was also evident by the absence of tumour nodules 
and normal appearance of the lungs (Fig. 3B).  Prior to injection, the mean level of L-selectin 
on F5LΔP T cells was 3-fold higher than on F5B6 T cells (Fig. 3C), as reported previously 
(19). L-selectin expression was maintained on F5LΔP T cells but completely downregulated 
on F5B6 T cells within 2 weeks of transfer into tumour bearing mice (Fig. 3D) demonstrating 
clearly the ability of the genetic mutant to resist ectodomain shedding as well as transcriptional 
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silencing in tumour-bearing mice. The activation status of injected T cells was not affected by 
L-selectin expression and injected F5B6, F5LselKO and F5 LΔP T cells comprised >94% 
CD44lo naïve T cells (Fig 3E).  The numbers, frequencies and extent of activation-induced 
degranulation (measured by CD107a mobilisation) of donor derived F5LΔP T cells in the lungs 
after 14 days were not significantly different from either F5B6 or F5L-selKO T cells (Figs. 3F, 
G and H).  The frequencies of CD44+CD27+ central memory T cells were higher in the F5LΔP 
population in the lungs, but not in the draining LN or spleen (Figs. 3I, J and K). Therefore, 
maintained L-selectin appears to have a role in the activation of tumour-specific T cells, as 
indicated by CD44 and CD27 expression at the site of the tumour, but not in tumour-draining 
LN or spleen.  
 
Impact of L-selectin on T cell homing in a solid tumour model 
L-selectin is an obligate homing molecule on naïve T cells for recruitment from the 
bloodstream into subcutaneous (peripheral) lymph nodes via specialised high endothelial 
venule (HEV) blood vessels (32).  Previous studies by Klebanoff et al showed that adoptive T 
cell therapy of L-selectin expressing CTLs did not have any anti-tumour effect in lymphotoxin-
α deficient mice, which lack lymph nodes (LN).  It was concluded that the role of L-selectin in 
adoptive T cell therapy is to direct homing of adoptively transferred CTLs to LN, although T 
cell homing to lymph nodes was not studied (15). HEV-like blood vessels expressing peripheral 
node addressin (PNAd), a ligand for L-selectin, have been reported in B16F10 melanomas and 
shown to support L-selectin dependent recruitment of T cells (33). This raises the possibility 
that L-selectin promotes homing of adoptively transferred naïve T cells from the bloodstream 
into the tumour via PNAd expressing tumour blood vessels, where T cells could be activated 
to kill tumour cells, without the need for LN entry.  To determine the role of L-selectin in T 
cell homing to LN and tumours in tumour-bearing mice, we used a competitive homing assay 
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that we have previously employed to determine the role of L-selectin in recruitment of CTLs 
from the bloodstream into virus-infected lungs (11).  F5LΔP and F5LselKO T cells (both 
Thy1.2) are mixed 1:1 and injected into Thy1.1 tumour-bearing mice.  This assay avoids the 
use of cell tracker dyes which may affect T cell trafficking and, unlike cell tracker dyes, the 
Thy1 marker is not diluted through cell division.  It also exploits the fact that L-selectin 
sufficient T cells (F5LΔP) can be distinguished from L-selectin deficient (F5 LselKO) T cells 
due to L-selectin expression which is maintained following T cell activation (11) and, as shown 
here, in tumour-bearing mice (Fig. 3D). The use of F5LΔP T cells also prevents the loss of L-
selectin from T cells after they have been recruited from the bloodstream into cancerous tissues. 
After 18 hours, the ratio of F5LΔP:F5-L-selKO T cells in tumours, spleen, blood, tumour-
draining and peptide-draining inguinal and axillary LN, and brachial LN were analysed by flow 
cytometry (Fig 4A). In our experience, brachial LN are not involved in draining the tumour in 
this model, whereas both inguinal and axillary LN have been observed to be tumour draining 
(data not shown). The brachial LN are therefore included to represent uninvolved, peripheral 
LN which depend on L-selectin for naïve T cell recruitment from the bloodstream via HEV 
(32).  
 
L-selectin sufficient and L-selectin deficient T cells were detected in approximately equal 
numbers in all peripheral LN analysed (tumour-draining and peptide-draining inguinal and 
axillary as well as brachial LN) (Fig. 4B). Although not significant, L-selectin expression 
conferred slightly improved homing to inguinal LN, but not to other peripheral LN (Fig 4B). 
These findings are in marked contrast to published data including own our studies in naïve and 
virus-infected mice where peripheral LN are highly enriched in L-selectin positive T cells (11, 
16, 32).  L-selectin sufficient and L-selectin deficient T cells were both found in the spleen 
(which  lack HEV), as reported previously (32), however, a higher proportion of L-selectin-
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deficient cells was observed in the blood which fits with previous observations that these cells 
are unable to traffic from the bloodstream into tissues (32). In contrast to expectations, F5 T 
cells were found associated with solid tumours 18 hours following intravenous administration.  
Moreover, L-selectin did not improve early homing of transferred T cells to the tumour, with 
the ratio of F5LΔP:F5B6 cells harvested from resected tumours remaining similar to the 
injected population. These results show clearly that the improved control of tumour growth by 
L-selectin enhanced T cells is not simply explained by increased homing either to LN or to the 
tumour within the first 18 hours following ACT.  
 
Impact of L-selectin on T cell activation in a solid tumour model 
The unexpected homing of L-selectin deficient T cells to peptide-draining and tumour-draining 
peripheral LN of tumour bearing mice, as well as to tumours, suggests that the lack of tumour 
growth control by F5LselKO T cells is not simply related to an inability to home to sites of 
tumour antigen-presentation in LN or tumours. In the absence of a clear role for L-selectin in 
T cell homing, we considered whether L-selectin expression controls T cell activation in 
lymphoid organs or inside tumours.  The expression of early activation marker CD69 on donor 
cells on the day of transfer in the competitive homing assay was quantified by median 
fluorescence intensity (MFI). Fold increase in expression of CD69 was subsequently calculated 
based on the MFI of donor T cells following recovery from tissues at the end of the study, 
compared to CD69 expression on T cell populations prior to transfer. CD69 expression was 
upregulated on L-selectin sufficient (F5LΔP) T cells harvested from tumour tissues 18 hours 
following transfer to tumour-bearing mice whereas CD69 on L-selectin deficient T cells 
(F5Lselko) was not increased (Fig. 4C). CD69 expression was upregulated on both L-selectin 
sufficient and L-selectin deficient T cells harvested from spleen of tumour bearing mice, 
however it was significantly higher on F5LΔP T cells compared to F5 L-selKO T cells (Fig. 
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4D). When L-selectin sufficient and deficient cells were harvested from the spleens of non-
tumour bearing mice which had undergone sub-lethal irradiation and peptide vaccination, there 
was a uniform increase in CD69 expression in both F5LΔP and F5 L-selKO T cells.  These 
data show that the conditioning regime of irradiation and peptide vaccination increases CD69 
equally on injected F5LΔP and F5 L-selKO T cells but it does not contribute to L-selectin-
dependent increases in CD69 expression.  Rather, the higher levels of CD69 on L-selectin 
sufficient T cells in the spleens of tumour-bearing mice are a direct consequence of tumour 
load (Fig. 4E). Representative plots showing the extent of CD69 upregulation on injected T 
cells in the spleens of tumour-bearing mice are shown in Figure 4F.   
 
In contrast to the spleen, CD69 expression on F5LΔP T cells and F5L-selKO T cells harvested 
from LN was variable and depended on LN location. In tumour-draining and peptide-draining 
axillary LN, CD69 was higher on L-selectin sufficient T cells whereas tumour-draining and 
peptide-draining inguinal LN, CD69 was upregulated equally (Fig. 4G). CD69 was upregulated 
on both L-selectin sufficient and L-selectin deficient T cells in brachial LN (Fig. 4G). As 
brachial LN is not a site of tumour antigen presentation, this finding suggests a role for the host 
conditioning regime in upregulating CD69 on F5LΔP T cells and F5L-selKO T cells as found 
in the spleens of non-tumour bearing mice (Fig. 4E). Together, these findings suggest that L-
selectin expression on adoptively transferred T cells does not promote homing to tumours or 
to LN.   Instead, L-selectin expression promotes early T cell activation as measured by CD69 
expression inside the tumour, spleen and involved LN. 
 
Longitudinal tracking of 89Zr labelled T cells in tumour bearing mice using PET-CT 
The localisation of CD8+ T cells isolated from naïve mice to tumours within 18 hours following 
intravenous injection was unexpected. It was predicted that T cells would require prior 
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activation by peptide-MHC complexes on APC in lymphoid organs and subsequent 
differentiation to effector T cells before being able to enter tumours from the bloodstream.  T 
cell activation takes longer than the 18-hour timeframe of the homing study (11, 34). To study 
the kinetics of T cell recruitment into tumours in individual mice following adoptive T cell 
therapy, we labelled F5 CD8+ T cells ex vivo with 89Zr oxine, as described previously for human 
T cells (35, 36), and injected 89Zr-labelled T cells to tumour bearing mice following the normal 
conditioning protocol of sub-lethal irradiation and peptide vaccination.  Mice were scanned 
within 1 hour following injection of T cells, rescanned the following day and at 1-2 day 
intervals thereafter.  89Zr was detectable in tumours, lungs, skeleton, liver, and spleen within 1 
hour following injection and for the following 5 days, but was not detected in heart, kidney or 
bladder (Fig. 5A and data not shown). To determine whether 89Zr remains associated with T 
cells following injection into mice or is released and excreted as waste, the predicted 
radioactive decay curve for total injected 89Zr was plotted alongside the actual amount of 89Zr 
detected in individual mice receiving either F5B6 or F5 LΔP T cells.  The total amount of 89Zr 
detected in a single mouse completely overlaid the predicted radioactive decay curves for both 
types of T cell indicating that cell-free 89Zr was not excreted during the course of the study 
(Figs. 5B and C). We also exploited the known kinetics of temporary intravascular trapping 
and release of T cells from the lungs (37) over the first 24-48 hours to assess whether 89Zr 
remains associated with T cells. The fraction of total 89Zr in the lungs of mice receiving F5B6 
T cells fell from 3-5 % at 1 h to ~ 1 % at 20 h after which it gradually increased over the 
following 5 days (Fig. 5C).  Lung associated 89Zr in F5LΔP recipients showed similar kinetics 
decreasing from 2 % at 1 hour to less than 1% at 20 hours (Fig. 5C) suggesting that 89Zr is T 
cell associated, at least for the first 20 hours following injection. The fraction of total 89Zr in 
the skeletons of mice receiving F5B6 T cells was ~4 % 1 hour after injection, increased 
gradually and stabilised at 6-8% at 44 hours after injection (Fig. 5D).  Skeletal localisation was 
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slightly lower in mice receiving F5LΔP T cells at 2% after 1 hour and gradually increased to 
~4% over the next 6 days (Fig. 5D).  Skeletal localisation of 89Zr did not exceed 8% of total 
89Zr, even after 140 h, which supports the hypothesis that the bulk of 89Zr is not being released 
as cell-free 89Zr during the course of the experiment which would be expected to localise to the 
skeleton (38).  89Zr was detectable in tumours within 1 h following intravenous injection of 
either F5B6 or F5LΔP T cells and 89Zr levels increased as tumours grew.  89Zr in tumours fell 
below the level of detection after 7 days, which is before the effects of ACT are detectable.  
Although these data suggest that 89Zr remains T cell associated for 7 days, we cannot formally 
exclude localisation of 89Zr in macrophages following death of T cells at time points beyond 
20 hours.  These studies did not allow a direct comparison between F5B6 and F5LΔP T cells 
in the same mouse, however, they do show clearly that both T cell populations localise to 
tumours within 1 hour of injection into the bloodstream. Taken together with the 18 hour 
homing data, this shows that there is extremely rapid localisation of T cells to solid tumours 
that is not dependent on L-selectin, followed by ongoing T cell accumulation over more than a 
week.   
 
End stage analysis of TILs and T cell proliferation 
To determine if maintained L-selectin alters the number of tumour infiltrating lymphocytes 
(TILs), the total numbers of CD3+ and CD8+ T cells were enumerated in tumour sections from 
solid tumours harvested at the end of the study (this could represent either an individual mouse 
culled due to tumour size, or animals sacrificed as a group at the end of the entire study). Mice 
were pooled from more than one experiment where experimental conditions were the same.  
As shown in Figure 6A, host-derived CD3+ T cells were readily detectable in tumours of mice 
which did not receive T cells (untreated).  The total numbers of CD3+ TILs (donor and host) 
were not significantly increased following transfer of either F5B6 or F5L-selKO T cells. The 
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total number of CD3+ TILs in the F5LΔP treatment groups was significantly increased by 
approximately 2-fold.  Similarly, the total number of CD8+ TILs in F5LΔP treated mice was 
significantly higher than in either F5B6 treated or untreated mice which had similar numbers 
CD8+ TILs (Fig. 6B).  The classical ligand for L-selectin, PNAd, was not detectable on tumour 
blood vessels using MECA79 antibody, although MECA79 positive HEV were detected in 
peripheral LN of naïve mice using the same staining procedure used for tumours (data not 
shown). 
 
These data show that the increased number of CD3+ TILs in F5LΔP recipients is not simply 
related to increased L-selectin dependent recruitment from PNAd expressing blood vessels 
inside the tumour either at the start of or during the course of ACT. This is supported by the 
disseminated tumour model, which does not rely on disordered tumour vasculature for T cell 
entry, but instead utilises the established and extensive lung vasculature. No increase in injected 
T cells was observed in the lungs of tumour-bearing mice, despite improved tumour control by 
F5LΔP T cells. Instead, it could reflect increased retention due to higher CD69 expression and 
possibly increased frequency of central memory CD44+ CD27+ T cells at the tumour site which 
are known to be more efficacious in mouse models of ACT (15) as found in the disseminated 
tumour model (Fig. 3I). We also considered whether the level of L-selectin on T cells 
determines other T cell properties that could contribute to the control of tumour growth.  Cross-
linking of L-selectin primes T-cells for antigen-induced proliferation (39) and controls 
important effector functions such as superoxide production (40), colony-stimulating factor 1 
release (41) and lytic activity (42), all of which may contribute to tumour cell killing.  Our 
previous studies of T cell dependent virus immunity have demonstrated that ectodomain 
shedding of L-selectin controls the clonal expansion of CD8+ T cells (43) so we started by 
analysing the impact of L-selectin on T cell proliferation. In the mouse tumour model, F5 T 
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cells are exposed to NP68 cognate peptide expressed on tumour cells and to exogenously 
injected or tumour derived peptide on APC in spleen and LN, as evidenced by CD69 
upregulation at these sites (Figs. 4E-G). To simulate continuous exposure of T cells to tumour 
antigen and measure T cell proliferation we exposed isolated T cells to peptide-pulsed APC in 
vitro and measured T cell proliferation and expression of the proliferation marker Ki67. Peptide 
stimulation was repeated every 7 days. As shown in Figure 6C, L-selectin expression is 
downregulated on F5B6 T cells over the first 7 days of stimulation and remains low following 
subsequent restimulations whereas F5LΔP cells maintain high levels of L-selectin throughout 
primary and subsequent re-stimulations. F5B6 undergo rapid clonal expansion during primary 
stimulation and T cell numbers peak after 7 days at 50 x 106/ml and gradually decline following 
restimulation (Fig. 6D). Proliferation of F5L-selKO T cells followed similar kinetics as F5B6 
cells showing early clonal expansion and subsequent contraction after 7 days. However, F5LΔP 
T cells showed a lag in proliferation which peaked later at 14 days. Moreover, the extent of 
clonal expansion of  F5LΔP T cells was smaller resulting in a 10-fold increase in T cell numbers 
at day 14, compared to F5B6  and F5L-selKO T cells which increased by ~20-fold by day 7. 
Analysis of Ki67 expression revealed differential patterns of expression in all three T cell 
populations.  Expression levels were categorised as low, medium or high (Fig. 6E) and showed 
different frequencies at each level between F5B6, F5LΔP and F5L-selKO T cells.  Statistically 
significant differences in the frequencies of Ki67 low cells were seen at day 3 and day 17 but 
not at later times (Fig. 6F). The decrease in the number of F5LΔP cells that are Ki67 low 
suggests that, despite the slower and overall lower level of proliferation, expression of the 
proliferation marker Ki67 was higher in F5LΔP cells. Whether this assay replicates the 
stimulation and expansion of F5LΔP T cells in tumour bearing mice is not known. However, it 
demonstrates that L-selectin enhanced T cells behave differently to cells expressing either 
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wildtype endogenous L-selectin or no L-selectin in response to immune stimulation in a model 
system where cell trafficking is not relevant.  
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Discussion 
L-selectin (also known as CD62L) is an important homing molecule on the surface of T cells 
for their recruitment from the bloodstream into lymph nodes where T cells first become 
activated by peptide-MHC complexes on dendritic cells.  L-selectin (CD62L), is commonly 
used as a marker of T cell activation, due to the well-documented observation that expression 
of L-selectin is downregulated when T cells are activated to CTL status. In mouse models of 
ACT, studies have shown that even when T cells are matched for activation status, L-selectin 
expressing CTLs confer an advantage over L-selectin knockout CTLs in controlling tumour 
growth (14). Based on these findings, we investigated the hypothesis that CTLs expressing a 
‘gain-of-function’ form of L-selectin that is never downregulated, even following T cell 
receptor engagement (LΔP; L-selectin enhanced), are better able to control the growth of solid 
cancers than wild type T cells which downregulate L-selectin expression. We report here that 
L-selectin enhanced T cells show improved control of tumour growth.  Previous studies have 
linked L-selectin to T cell function due to differential homing of L-selectin expressing 
naïve/central memory T cells to lymph nodes and L-selectin negative effector/effector memory 
T cells to non-lymphoid/ inflamed tissues.  In this study, we show clearly that the effect on 
tumour growth is unrelated to L-selectin dependent homing but instead correlates with early 
activation of therapeutic T cells inside tumours. 
In two different tumour models, T cells expressing LΔP-selectin were better able to control the 
growth of transplanted tumours than wild type T cells. These findings support the hypothesis 
of the study and show clearly that maintaining L-selectin expression is beneficial for adoptive 
T cell tumour therapy.  L-selectin enhanced T cells controlled the growth of solid, vascularised 
subcutaneous tumours as well as disseminated tumours which had colonised the lungs showing 
that the effect of L-selectin enhanced T cells is not restricted by tumour location or size at the 
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start of therapy. Clinically, the most marked effects of cancer immunotherapy have been 
achieved through the use of checkpoint blockade inhibitors.  In the solid tumour model, 
checkpoint blockade inhibitors did not control tumour growth in the absence of T cell transfers. 
However, anti-CTL-4 and anti-PD-1 monoclonal antibody therapy showed marked synergy 
with the transfer of T cells expressing wild type L-selectin resulting in arrest of growing 
tumours. This powerful synergy is also demonstrated by the combination of anti-PD-1 with 
F5LΔP CD8+ T cell transfer.  
The obvious mechanism for control of tumour growth by F5 LΔP T cells would be improved 
trafficking into the tumour. Indeed, the motivation behind applying this molecule to ACT is 
based on our own findings of improved anti-viral immunity due to homing of LΔP T cells to 
virus-infected lungs (11). Increased numbers of CD3+ and CD8+ cells were identified in solid 
tumours in mice treated with F5LΔP cells compared to either wild type or L-selectin knockout 
T cells at experimental endpoints. However, increased TILs in solid tumours up to 30 days 
after transfer could be due to a range of scenarios, including improved homing, increased 
proliferation, increased retention or prolonged survival. To determine the kinetics of T cell 
recruitment from the bloodstream into solid tumours, we tracked 89Zr labelled T cells following 
transfer to tumour-bearing mice by PET/CT.  Since therapeutic T cells were not pre-activated 
prior to transfer, we expected a lag between T cell injection and localisation of CTLs inside 
tumours which would reflect activation in secondary lymphoid organs of tumour-bearing mice. 
However, tumour-specific T cells were detected inside tumours within 1 hour of injection into 
the bloodstream. 89Zr label steadily increased inside solid tumours over the subsequent 8 days 
of tumour growth which is before the therapy took effect. Wild type T cells and L-selectin 
enhanced T cells were tracked in the tumour at every time point including 1 hour after transfer. 
Although direct comparison of different T cell populations in the same tumour-bearing mouse 
was not possible using this method, it did demonstrate that F5B6 (unmodified) T cells are able 
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to enter the tumour, and therefore the benefit of maintaining L-selectin is not simply a case of 
licensing T cells to enter the tumour stroma.  When L-selectin positive and L-selectin knockout 
T cells were compared directly in a competitive homing assay, no evidence of L-selectin 
dependent homing to tumours was observed.  A single report describes induction of PNAd on 
tumour blood vessels in B16 melanomas expressing the surrogate tumour antigen OVA in 
peritoneal, but not subcutaneously, growing tumours which supports recruitment of naïve L-
selectin expressing T cells (33). The absence of PNAd expressing tumour blood vessels and L-
selectin dependent homing of T cells in subcutaneously growing NP68-B16 tumours agrees 
with this published report. Most studies of T cell homing to tumours have focussed on the 
recruitment of effector T cells into B16 melanomas and shown important roles for P/E-selectin 
and ICAM-1 on tumour blood vessels as well as CXCR3 ligands (44, 45). Further studies will 
be therefore be required to determine which adhesion molecules and chemokines control L-
selectin independent recruitment of unactivated, therapeutic T cells into solid tumours that our 
studies have revealed.  
An alternative explanation for the beneficial effects of LΔP-selectin expressing T cells is to 
sustain trafficking to lymph nodes where T cells are licensed by activating, tolerogenic or 
homeostatic signals which could affect the differentiation and/or survival of F5 LΔP T cells. 
However, F5 LΔP T cells and F5 L-selectin knockout T cells homed equally well to peripheral 
lymph nodes in tumour bearing mice at the start of therapy. The loss of L-selectin dependent 
homing of T cells to peripheral lymph nodes in tumour-bearing mice contrasts sharply with our 
own findings and published studies using similar competitive homing assays where T cell 
homing to peripheral LN in both naïve and virus infected mice is exquisitely L-selectin 
dependent (11, 16, 32, 46) Although not explored further, a likely explanation is induction of 
MAdCAM-1 on HEV in peripheral LN of tumour bearing mice which occur in immunised 
mice (47).  Co-expression of PNAd and MAdCAM-1, which binds both α4β7 integrin and L-
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selectin on T cells (48, 49), would allow entry of L-selectin expressing and L-selectin knockout 
T cells into peripheral LN, as we have found.  Previous studies have shown that B16F10 
melanoma regulate CCL21 dependent T cell recruitment from HEV blood vessels in tumour 
draining LN but the role of L-selectin was not explored (50).  
Although equal numbers of F5LΔP and F5 L-selectin knockout T cells reached solid tumours, 
the activation of T cells was different. Prior to transfer, unactivated T cells had equally low 
expression of CD69. However, 18 hours after transfer, CD69 expression was upregulated on 
F5LΔP cells but not on F5L-selectin knockout T cells inside tumours.  Although CD69 was 
upregulated on both F5LΔP cells and F5 L-selectin knockout T cells inside lymph nodes and 
spleen, CD69 was significantly higher on F5LΔP cells, particularly in the spleen. In non-
tumour bearing animals which had been irradiated and vaccinated with peptide, CD69 was 
equally upregulated on F5LΔP cells and F5 L-selectin knockout T cells in the spleen.  
Therefore, L-selectin enhanced T cells respond to the presence of a tumour differently to L-
selectin knockout T cells and upregulate CD69 both inside the tumour and at sites of antigen 
presentation and priming in secondary lymphoid organs. This is the first report, to our 
knowledge, that the combination of tumour load and L-selectin status changes the activation of 
T cells in vivo independently of effects on homing.  The steady increase in 89Zr in tumours 
following transfer of L-selectin expressing T cells suggests that T cells continue to be recruited 
over the first 7 days of therapy, but where incoming T cells were before entering the tumour 
and whether they are already activated is not possible to determine by PET scanning. Whether 
CD69 expression is maintained on activated F5LΔP tumour infiltrating T cells throughout the 
course of the therapy and increases the number of CD8+ tumour infiltrating T cells due to 
retention will be interesting to address.  L-selectin does not control the differentiation of CTLs 
in tumour bearing mice, at least in the lungs, where CD107a expression on transferred T cells 
was unrelated to L-selectin expression. However, L-selectin controls other aspects of T cell 
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activation as shown by increased numbers of CD44+ CD27+ ‘central memory’ F5LΔP cells in 
the lungs of tumour bearing mice as well as Ki67 expression and altered proliferation ex vivo. 
Further studies will be required to fully dissect the mechanism(s) underlying L-selectin 
dependent control of T cell activation, differentiation and proliferation. Which of these 
pathways underlies the beneficial effects of F5LΔP T cells in adoptive cell tumour therapies 
and whether they differ for solid and disseminated tumours will be important to address. Since 
L-selectin knockout T cells do not control tumour growth yet CD69 is upregulated in secondary 
lymphoid organs, it is unlikely to be related to events in lymph nodes or spleen. The striking 
finding that CD69 is not upregulated on L-selectin knockout T cells in solid tumours suggests 
that the beneficial role of L-selectin is linked to activation of therapeutic T cells inside tumours.  
The dominant role of L-selectin in controlling T cell homing has focused attention on its 
adhesive function. The impact of F5LΔP T cells on tumour growth correlated with increased 
cell surface expression of L-selectin rather than altered levels of soluble L-selectin.  Maintained 
expression of L-selectin at the T cell surface could prolong binding to accessory cells 
expressing non-PNAd ligands for L-selectin, such as PSGL-1 (51) or MAdCAM-1 (48), and 
alter transmission of co-stimulatory signals to T cells resulting in increased expression of 
CD69.  L-selectin dependent upregulation of CD69 was seen in tumours and lymphoid organs 
suggesting that a ligand-expressing accessory cell is unlikely to be tumour cells but an antigen-
presenting cell that matures in the tumour microenvironment and re-locates to lymphoid 
organs.  Although other mechanisms are possible, it is striking that the increased efficacy of 
F5LΔP T cells against pulmonary influenza infection differs fundamentally from the findings 
reported here because it is not related to altered T cell activation, differentiation or cytotoxicity 
but instead depends on increased homing of CTLs to virus-infected lungs (11).  
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Despite remarkable successes in the field of cancer immunotherapy, many solid tumours 
remain beyond the reach of this approach. One factor that is believed to be problematic is the 
recruitment of immune cells (endogenous or exogenous) into the tumour stroma, due to the 
atypical nature of tumour vasculature (7). In clinical and experimental cancers, the 
development of PNAd expressing HEV correlates with improved patient outcome (52, 53) and 
the control of tumour growth (33, 54, 55).  L-selectin enhanced T cells might be reasonably 
hypothesized to have an even greater effect where PNAd-expressing tumour vasculature 
develop, such as in response to immunotherapies (33, 54, 55). The fact that L-selectin is both 
shed and gene-silenced in the course of normal T cell activation poses potential challenges for 
translation of this approach. However, the advent of 2nd generation CAR-T cell therapies which 
involve multiple modifications, means that the gain-of-function modification used in these 
studies could be applied to CAR-T cells to broaden their clinical scope.  However, monitoring 
endogenous L-selectin expression on TILs or CAR-T cells may be of immediate clinical benefit 
in the sel ection of T cell subsets for administration to cancer patients. The fact that we observed 
improved control of tumour growth independently of homing, which is associated with 
alterations in early activation, and works in combination with checkpoint blockade inhibitors 
makes enhancing L-selectin expression a high-value modification that is likely to improve 
several aspects of T cell function in the fight against cancer.   
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Table 1. Mouse Genotypes.   
 
  
Mouse ID Background  F5 TCR 
Endogenous 
L-selectin 
CD62L 
transgene 
Thy 
Tumour 
bearing 
host or T 
cell 
donor 
C57BL/6 
(B6) 
B6 no +/+ no Thy1.2 
Host 
Thy1.1 B6 no +/+ no  Thy1.1 
Host 
FoxP3DTR B6 no +/+ no Thy1.2 
Host 
CD62Lwt B6 no -/- 
wildtype 
hemizygous 
Thy1.2 
Host 
CD62LΔP B6 no -/- 
LΔP  
hemizygous 
Thy1.2 
Host 
F5B6 B6 homozygous +/+ no Thy1.2 Donor 
F5LselKO B6 homozygous -/- no Thy1.2 Donor 
F5LΔP B6 homozygous -/- 
LΔP  
homozygous 
Thy1.2 
Donor 
F5/B6 B6 hemizygous +/+ no Thy1.2 Donor 
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Figure 1: An immunogenic solid tumour model in mice.  
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(A) B16 melanoma cells expressing the NP68 antigen were transplanted subcutaneously 
into immunocompetent mice. 7 days after tumour transfer, mice were treated 
intravenously with either naïve CD8+ T cells carrying the F5 TCR, or CD8+ T cells 
activated in vitro with NP68 peptide (CTLs). F5B6 cells are homozygous and F5B6/B6 
cells are hemizygous for the F5 TCR. Growth rates of tumours over time were 
measured in two dimensions and a ‘k’ value was calculated. Data from more than one 
experiment. Scatter plots show individual mice and bars show means and SEM. 
(Untreated, n = 41, F5B6 CTLs, n = 14; F5B6/B6 CTLs, n = 6; naïve F5B6 T cells, n 
= 10). (B) NP68-B16 cells were transplanted into FoxP3DTR mice, and 7 days 
following tumour transfer, half the mice were treated with 5µg/kg DT diphtheria toxin 
(DT) every 3 days for 2 weeks, n=6. (C) NP68-B16 cells were transplanted into 
FoxP3DTR mice, and 7 days following tumour transfer mice were treated with either 
5µg/kg DT, 2.5µg/kg DT, 200mg/kg cyclophosphamide (CY) or 100mg/kg 
cyclophosphamide. After 7 days of treatment, peripheral blood was sampled from the 
tail vein, and the percentage of cells positive for TCR and FoxP3 was enumerated by 
flow cytometry. Scatter plots show individual mice and bars show means. (D) Tumour 
growth rates in mice receiving different host conditioning regimes. Mice were 
conditioned 7 days following tumour transfer by sublethal irradiation and peptide 
adjuvant (C57BL/6 hosts), CY or DT treatment (FoxP3DTR hosts), n= 10-14. Data 
from more than one experiment. Differences in tumour growth rate were calculated by 
linear regression and significances indicate differences in slope. *** = P≤0.001. (E) 
C57BL/6 mice with NP68-B16 tumours established for 7 days were treated with 
sublethal irradiation (597cGy) and peptide adjuvant together with naïve CD8+ T cells 
carrying the F5 TCR or polyclonal T cells (C57BL6). T cell doses were 5 x 104 = Lo; 
2.25 x 105 = Med; 5 x 105 = High; n=7-8. (F) C57BL/6 mice with NP68-B16 tumours 
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established for 7 days were treated with sublethal irradiation (597cGy) and peptide 
adjuvant together with 2.25 x 105 naïve CD8+ T cells carrying the F5 TCR in addition 
to treatment with anti-CTLA-4 antibody on days 9, 12 and 15 post tumour transfer, 
n=8. (G) C57BL/6 mice with NP68-B16 tumours established for 7 days were treated 
with sublethal irradiation (597cGy) and peptide adjuvant together with 5 x 104 naïve 
CD8+ T cells carrying the F5 TCR in addition to treatment with anti-PD-1 antibody at 
10, 13 and 16 days post tumour transfer, n=5-9 (A, C) Significance was calculated 
using one-way ANOVA with Tukey’s multiple comparisons test. ***, P≤0.001. **, 
p<0.01. (D-G) Differences in tumour growth rate were calculated by linear regression 
and significances indicate differences in slope compared to untreated groups. ** 
P≤0.001; *** P≤0.001. 
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Figure 2: L-selectin enhanced T cells expressing gain-of-function L-selectin exhibit 
improved control of solid tumour growth.  
(A) B16-F10 melanomas were grown subcutaneously in unmanipulated C57BL/6 (B6) mice or 
transgenic mice expressing either wildtype (CD62Lwt) or gain of function (CD62LΔP) L-
selectin and tumour growth measured in the absence of host conditioning. Data represent the 
survival of mice with tumours ≥ 200mm3. n=11-13 mice per group. (B) C57BL/6 mice with 
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NP68-B16 tumours established for 7 days were treated with sublethal irradiation (597cGy) and 
peptide adjuvant together with 5x105 naïve CD8+ T cells carrying the F5 TCR and either WT 
(F5B6) or gain-of-function L-selectin/CD62L (F5LΔP), n=7-8. The Untreated control group 
for this experiment has been published previously (22). The experiment was a multi-arm study, 
with a shared control group, for the purposes of Replacement, Refinement and Reduction of 
Animals in Research in the UK (3Rs). The F5 T cell-treated groups have not been published 
previously. (C) Flow cytometric analysis of CD8+ T cells prior to adoptive transfer, indicating 
levels of CD62L and transgenic F5 TCR. Gray histograms are background staining. Graphic 
show L-selectin expression and shedding in different T cell populations. (D) Effect of the F5 
T cell populations shown in (C) on NP68-B16 tumours established for 7 days and conditioned 
with sublethal irradiation and peptide adjuvant, n=10. (E) Tumour growth curves for individual 
animals in experiment (D). (F) Soluble L-selectin in naïve C57BL/6 mice and tumour-bearing 
hosts (TBH) without (untreated) and with F5 T cell therapy. Symbols are data from individual 
mice. Results are mean + SEM. Significance tested using one-way ANOVA and Tukey’s 
multiple comparison test. * p<0.05. (G) Synergy between checkpoint blockade inhibition and 
L-selectin expressing T cells. Effect of F5LΔP T cells with and without anti-PD1 therapy (n=8).  
Differences in tumour growth rate compared to untreated groups and between treatment groups 
were calculated by linear regression. * P≤0.05; ** P ≤0.01; *** P ≤0.001 
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Figure 3: L-selectin enhanced T cells expressing gain-of-function L-selectin exhibit 
improved control of disseminated tumour growth. 
(A) Experimental protocol schematic. Both NP68-B16 tumour cells and naïve CD8+ cells were 
introduced via intravenous injection. (B) Tumour load measured by representage images of H 
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& E stained lung sections and total lung mass. Data are pooled from more than one experiment. 
Symbols show individual mice and bars show means. Solid and dashed black lines show mean 
lung weight ± SD in age- and sex-matched naïve mice (56). Graphic shows L-selectin 
expression and shedding in different T cell populations. (C) Fold increase in expression of 
CD62L on F5LΔP naïve CD8+ T cells compared to F5B6 and F5L-selKO CD8+ T cells. (D) 
CD62L expression of donor T cells recovered from the lungs of tumour bearing hosts on day 
14, measured by mean fluorescence intensity.  (E) CD44 and CD27 expression on donor CD8+ 
T cells prior to adoptive transfer. (F, G) Donor cells recovered from tumour-bearing lungs, by 
total number (F) and percentage CD8+ cells (G). (H) Expression of CD107a on donor T cells 
recovered from tumour-bearing lungs, measured by mean fluorescence intensity. (I) Percentage 
of donor T cells recovered from tumour-bearing lungs that are positive for CD44 and CD27. 
(J) Percentage of donor T cells recovered from spleen that are positive for CD44 and CD27. 
(K) Percentage of donor T cells recovered from the lung-draining lymph nodes that are positive 
for CD44 and CD27. (B, D, F-K) Significance was calculated using one-way ANOVA with 
Tukey’s multiple comparisons test. ***, P≤0.001, **, P≤0.01, *, P≤0.05.  
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Figure 4: L-selectin dependent T cell homing and activation in tumour bearing mice. 
(A) Schematic of in vivo homing study and the location of lymph nodes in relation to tumour 
and peptide adjuvant injections. Diagram is of ventral view of mice showing various LNs. (B) 
Competitive homing of L-selectin sufficient (F5LΔP) and L-selectin deficient (F5 L-selectin 
ko) naïve T cells. T cells were allowed to home for 18 hours before being recovered and 
analysed by flow cytometry based on expression of F5 and L-selectin transgenes. Values are 
normalised to a total donor cell population of 100%. TDALN, tumour draining axillary lymph 
node; TDILN, tumour draining inguinal lymph node; PDALN, peptide draining axillary lymph 
node; PDILN, peptide draining inguinal lymph node; BLN, brachial lymph node. (C-G) 
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Expression of activation marker CD69 on donor T cells recovered from tumour, spleen and LN 
calculated as fold increase over pre-transfer expression. Pre-transfer CD69 MFI values were 
1580 for F5LselKO cells and 1664 for F5LΔP cells. (C) CD69 expression levels on donor T 
cells recovered from tumours of mice 18 hours after injection. (D) CD69 expression levels on 
donor T cells recovered from spleens of tumour-bearing hosts after 18 hours. (E) Comparison 
of CD69 expression on donor cells recovered from the spleens of tumour-bearing hosts (TBH) 
and non-TBH after 18 hours, in a competitive homing study similar to that described in (A).  
(F) Representative plots showing CD69 expression on donor T cell pre-transfer to tumour 
bearing mice and following isolation from spleens of tumour-bearing mice (post-transfer). 
Percentages of CD69 positive donor T cells are shown. (G) Comparison of CD69 expression 
on donor cells recovered from the LN of tumour-bearing hosts after 18 hours, in a competitive 
homing study similar to that described in (A). (B, G) Bars show means + SEM (n = 5 ) (B, C, 
D, E and G) Significance was calculated using two-way ANOVA and multiple t-test. ***, 
P≤0.001. **, P≤0.01. *, P≤0.05. 
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Figure 5: Longitudinal tracking of 89Zr labelling T cells in tumour bearing mice using 
PET-CT. 
(A) Representative PET-CT images of NP68-B16 tumour bearing B6 mice 5 days after 
intravenous injection of 89Zr labelled T cells. T, tumour. Image orientations: 1, Maximum 
intensity projection; 2, Sagittal; 3, Coronal; 4, Transverse. (B) Representative time-activity 
curves from dosimeter quantification of 89Zr in the whole mouse overlaid with predicted 
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radioactive decay of 89Zr in recipients of F5B6 (left) and F5LΔP (right) T cells. (C, D) Time-
activity curves from image-based quantification of 89Zr in the lungs (C) and skeletons (D) of 2 
mice receiving F5B6 (red) or F5LΔP (blue) T cells expressed as percentage of total 89Zr in the 
mouse at each timepoint. The earliest time point in B, C and D is 1 h after injection. (E, F) 
Time-activity curves from image-based quantification of 89Zr in tumours expressed as 
percentage of total 89Zr in the mouse (blue line) overlaid with tumour size measured by CT 
(volume; green line). Graphs show overlaid curves from each of two mice receiving either 
F5B6 (E) or F5LΔP (F) T cells.  
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Figure 6: Impact of L-selectin on TILs and T cell proliferation ex vivo. 
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(A, B). Subcutaneous tumours were fixed in formalin and embedded in paraffin. 5 µm sections 
were stained for CD3 (A) and CD8 (B) and images analysed using Fuji Image J software.  Each 
symbol represents % area stained in tumours from single mice receiving no T cells (untreated), 
T cells expressing endogenous L-selectin (F5B6), no L-selectin (F5 LselKO) or enhanced L-
selectin (F5LΔP). Data are pooled from more than one experiment conducted under identical 
conditions.  Bars show means (Untreated, n = 5-12, F5B6, n = 9-11; F5L-sel KO, n = 4; F5LΔP, 
n = 7-10). (C) CD8+ T cells from F5B6, F5LΔP and F5L-selectin ko mice were stimulated in 
vitro on NP68-peptide pulsed APCs, with restimulation every 7 days. Every 3 days, a sample 
of cells was collected, and analysed by flow cytometry for a range of markers, including 
CD62L, n=2-3. (D) Total live cells were enumerated by haemocytometer at each timepoint. 
(E) The proliferation marker Ki67 was compared on the same cell populations at days 3, 7 and 
17. (F) The frequency of Ki67lo cells at each time point. (A, B, F) Significance was calculated 
using one-way ANOVA with Tukey’s multiple comparisons test. ***, P≤0.001. **, P≤0.01. *, 
P≤0.05. 
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